Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prognostic factors in lymphomas].

Emmanuel Bachy1, Gilles Salles

  • 1Hospices civils de Lyon, Université Claude-Bernard, Service d'hématologie Centre hospitalier Lyon-Sud, 69496 Pierre-Bénite Cedex.

La Revue Du Praticien
|March 13, 2010
PubMed
Summary

Identifying prognostic factors is crucial for predicting lymphoma patient outcomes and guiding treatment decisions. Established clinical factors and emerging molecular biomarkers aid in personalizing lymphoma care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR in R/R FL: is real-world efficacy meeting expectations?

Blood advances·2026
Same author

Marginal Zone Lymphoma With T-Follicular Helper Hyperplasia: Paving the Way for New Concepts in Cellular Plasticity and Unveiling Histopathologic Pitfalls.

The American journal of surgical pathology·2026
Same author

Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression.

Nature communications·2026
Same author

Comparative effectiveness of odronextamab monotherapy <i>versus</i> real-world systemic therapies in R/R follicular lymphoma.

Leukemia & lymphoma·2026
Same author

Nodal T-follicular helper cell lymphoma with clonal B-cell component: a distinct mutational profile and aggressive clinical behavior.

Leukemia & lymphoma·2026
Same author

Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis.

HemaSphere·2025

Area of Science:

  • Hematology
  • Oncology
  • Molecular Diagnostics

Context:

  • Accurate prediction of lymphoma patient outcomes is essential for treatment planning.
  • Current prognostic assessments rely on pathological subtype and clinical factors like age, performance status, disease stage, and lactate dehydrogenase (LDH) levels.
  • These factors are integrated into prognostic indexes for various lymphoma subtypes.

Purpose:

  • To highlight the necessity of prognostic factors in lymphoma patient management.
  • To review established clinical prognostic indicators.
  • To introduce the potential of molecular biomarkers in refining prognostic assessments.

Summary:

  • Prognostic factors are vital for informing patients and selecting optimal treatments for lymphoma.
  • Clinical factors such as age, performance status, Ann Arbor stage, and LDH levels are routinely used to establish prognostic indexes.
  • Emerging molecular biomarkers, analyzed using molecular techniques on tissue samples, show promise for future optimization of clinical care.

Impact:

  • Improved patient counseling and treatment selection for lymphoma.
  • Enhanced prognostic accuracy through the integration of clinical and molecular data.
  • Potential for more personalized and effective therapeutic strategies in lymphoma management.

Related Experiment Videos